Infliximab is an effective glucocorticoid-sparing treatment for Takayasu arteritis: Results of a multicenter open-label prospective study.
Autoimmun Rev
; 19(10): 102634, 2020 Oct.
Article
in En
| MEDLINE
| ID: mdl-32801040
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Takayasu Arteritis
/
Antirheumatic Agents
/
Infliximab
/
Glucocorticoids
Type of study:
Clinical_trials
/
Etiology_studies
/
Observational_studies
/
Risk_factors_studies
Limits:
Adult
/
Female
/
Humans
/
Male
Language:
En
Journal:
Autoimmun Rev
Journal subject:
ALERGIA E IMUNOLOGIA
Year:
2020
Document type:
Article
Affiliation country:
Country of publication: